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Metallothioneins (MTs) belong to a group of small cysteine-rich proteins that are ubiquitous 
throughout all kingdoms. The main function of MTs is scavenging of free radicals and 
detoxification and homeostating of heavy metals. In humans, 16 genes localized on 
chromosome 16 have been identified to encode four MT isoforms labelled by numbers (MT-1 
– MT-4). MT-2, MT-3 and MT-4 proteins are encoded by a single gene. MT-1 comprises 
many (sub)isoforms. The known active MT-1 genes are MT-1A, -1B, -1E, -1F, -1G, -1H, -1M 
and -1X. The rest of the MT-1 genes (MT-1C,-1D,-1I,-1J and -1L) are pseudogenes. The 
expression and localization of individual MT (sub)isoforms and pseudogenes vary at intra-
cellular level and in individual tissues. Changes in MTs expression are associated with the 
process of carcinogenesis of various types of human malignancies, or with a more aggressive 
phenotype and therapeutic resistance. Hence, MT (sub)isoforms profiling status could be 
utilized for diagnostics and therapy of tumour diseases. This review aims on a comprehensive 
summary of methods for analysis of MTs at (sub)isoforms levels, their expression in single 
tumour diseases and strategies how this knowledge can be utilized in anticancer therapy.  
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Metallothioneins (MTs) are a group of low molecular mass, cysteine-rich proteins that have 
been found in bacteria, plants, invertebrates and vertebrates (Cai, et al., 2014; Ruttkay-
Nedecky, et al., 2013). In mammals, number of amino acids in MTs varies from 61 to 68, 
from which 20 or 21 are 20 cysteines. Due to high thiol groups content, MTs are able to bind 
12 monovalent or 7 divalent metal ions and their main functions include maintaining 
homeostasis of essential metals (Cu and Zn), detoxification of toxic metal ions (Cd) and 
scavenging free radicals to protect cells against oxidative stress (Klaassen, Liu, & Diwan, 
2009). MT-encoding genes are located on chromosome 16 in a cluster and involve 16 
identified genes, from which five are pseudogenes. Two pseudogenes and one MT-like gene 
are located elsewhere, for details see Table 1. In humans, four MT isoforms exist, labelled by 
numbers (MT-1 – MT-4). MT-2, MT-3 and MT-4 proteins are encoded by a single gene. MT-
1 comprises many subtypes encoded by a set of 13 MT-1 genes. The known active MT-1 
genes are MT-1A,-1B, -1E, -1F, -1G, -1H,-1M and -1X. The rest of the MT-1 genes (MT-1C,-
1D,-1I,-1J and -1L) are pseudogenes whose protein product has not been found in humans 
(Cai, et al., 2014; Romero-Isart & Vasak, 2002). Summary of MTs genes, (sub) isoforms, loci 
and synonyms is shown in Table 1. The most distinctive differences can be found comparing 
MT-1/MT-2 with MT-3, which contains a conserved acidic hexapeptide insert near the C-
terminus in the α-domain, additional threonine residue in β-domain and a unique pair of 
prolines (-TCPCPS-) near the N-terminus in the β-domain, which are essential for biological 
activity of MT-3, heavy metals binding properties and association with other proteins, which 
suggest function diversification in various physiological processes (Bogumil, et al., 1998).  
MT-1 and -2 are the most widely expressed in the body, occurring predominantly in tissues of 
kidney, liver, intestine and pancreas. MT-3 is found mainly in the brain, but it is also 















deciduae (Wei, et al., 2008). Other differences can be found at the level of the expression and 
localization of individual MT (sub)isoforms, which vary at intra-cellular level (cytosol, 
nucleus, mitochondria and lysosomes) and also in individual tissues (Moleirinho, et al., 2011; 
Sharma, Rais, Sandhu, Nel, & Ebadi, 2013; Thirumoorthy, et al., 2011).  
Questions regarding a purpose of a high number of MT (sub)isoforms and genes arise with 
increasing knowledge. Even though differences between affinity to zinc and other metals 
among single isoforms have been found, as well as susceptibility to antioxidants, these 
differences do not justify such a high number of isoforms, which, as we anticipate, have to 
have some further biological importance (Schmidt & Hamer, 1986). Mammalian MT-1 and 
MT-2 are transcriptionally induced conserved proteins essential for metals binding. In most 
mammalian genomes one copy of MT-2, MT-3, MT-4 and multiple copies of MT-1 are 
present. Specifically, in human genome, 13 MT-1 genes are present, from which 5 are 
pseudogenes. The highest number of MT-1 copies is found in primate genomes indicating the 
relatively recent duplication events. The process of gene duplication contributes to phenotypic 
diversity of living organisms. Novel gene functions arise from mutations altering the sequence 
of gene product or affecting gene expression. Dynamic changes in tissue expression 
preference of paralogs with different duplication ages suggest differential contribution of 
paralogs to specific organ functions. Paralogs are enriched for genes with brain-specific 
expression and provide evidence for differential forces underlying the preferential emergence 
of young testis- and liver-specific expressed genes (Guschanski, Warnefors, & Kaessmann, 
2017). Phylogenetic analyses show that MT-1 pseudogenes are derived from functional genes 
by loss of invariant cysteines and incorporation of aromatic amino acids, and thus 
accumulation of loss-of-function mutations. The sequence of MT-4 is highly conserved 
between humans and mice, but it shows the highest divergence in humans with two 















African and Asian populations suggesting its non-functionality in some individuals. Some 
MT-1 duplicates have cellular specificity and some of them are expressed in epithelium. 
Taken together with similarities between mouse MT-1 and MT-4 structural and metal binding 
properties it is possible that the high number of MT-1 genes compensates and backs-up the 
loss of MT-4 gene (Moleirinho, et al., 2011). These findings indicate that the change in 
expression of single MT genes should be changed in the process of carcinogenesis. In the 
present review we attempt to summarize up-to-date knowledge on the role of MTs 
(sub)isoforms with special emphasis on their roles in malignant diseases (Fig. 1). Due to the 
fact that MTs could be helpful as diagnostic and/or prognostic biomarkers in several types of 
cancers, we also discuss the bioanalytical methods, which enable determination of MTs on 
(sub)isoform levels. Last but not least, we put our attention on a regulation of MTs by 
epigenetic processes, whose importance has been evidenced in most of malignancies, and on 
utilization of regulation of MTs to enhance efficiency of cancer therapy, too. 
 
Methods enabling estimation of MT isoforms and (sub)isoforms  
It is clear from the above-mentioned facts that MT exists as a mixture of variable forms. This 
broad heterogeneity leads to the need for development of powerful separation and 
bioanalytical techniques that enable the study and understanding of the importance of 
individual MT (sub)isoforms, however, this is still challenging task. Although there is a high 
chemical and structural similarity among the isoforms, single MTs are involved in various 
processes and their expression is dependent on a particular process and tissue. Expression of 
MTs can be monitored both on nucleic acid level and protein level (Fig. 2), i.e. MT protein 
presence and its modifications, especially metalation, oxidation, acetylation and methylation 
(Ogra & Suzuki, 1999; Ryvolova, et al., 2011). However, due to the high structural similarity 















Therefore the most frequent methods for assessment of single MT isoform expression are 
nucleic-acids based methods, such as in situ hybridization, (Q)-RT-PCR and microarrays 
(Albrecht, et al., 2008; Han, et al., 2013; Krizkova, et al., 2016). These methods allow for 
detection of MT genes polymorphisms, regulation of MT expression both based on MT 
mRNA synthesis and/or degradation by mechanisms of RNA interference either by 
determination of mRNA, small RNA or non-coding long RNA presence (J. Yang, et al., 
2017). Determination of mRNA does not reflect the amount of MT proteins due to the 
different mRNA induction and degradation rates as well as RNA-based regulation 
mechanisms. Thus, determination of both MT protein and mRNA can be useful to obtain 
complete information (Fig. 2). 
For determination of MT proteins, the most of the methods are based on specific chemical 
properties of MT, especially high thiol groups content and heavy metals content, on which are 
based Elman’s assay, electrochemical and metal-saturation methods, respectively 
(Bienengraber, Forderkunz, Klein, & Summer, 1995; Dutton, Stephenson, & Klaverkamp, 
1993; Krizkova, et al., 2009; Ryvolova, et al., 2011; Savas, Shaw, & Petering, 1993). These 
methods do not allow distinguishing of specific MT protein isoforms, even though the 
differences in redox potential and heavy metals affinity have been found. To detect MT 
isoforms in biological samples, antibody-based methods such as immunohistochemistry, 
immunocytochemistry, ELISA and western-blotting are most frequently used. Predominantly, 
the antibodies recognizing MT-1+2 and MT-3 are employed. Due to a high structural 
similarity between MT-1 and MT-2 isoforms, the development of isoform-specific antibodies 
is an issue. First the MT-1 and MT-2 isoforms have to be separated or produced by 
recombinant DNA technology and the obtained antibodies has to be purified from isoform-
cross-reactive immunoglobulins (H. M. Chan, Pringle, & Cherian, 1992). Distinguishing of 















sequence and structural homology, however commercially available anti-MT-1G and anti-
MT-1A antibodies have been used for verification of Q-RT-PCR and RNA interference (X. F. 
Sun, et al., 2016). Antibodies specific to MT-3 most frequently recognize the additional N-
terminal 6-amino acid-containing domain, which is specific for MT-3 only (Sens, Somji, 
Garrett, Beall, & Sens, 2001). 
Other methods for analysis of MT on a protein level comprise a broad range of spectroscopic 
methods hyphenated with different separation techniques. Of them, the most predominant are 
capillary electrophoresis or high-performance liquid chromatography coupled with mass 
spectroscopy (CZE-MS or HPLC-MS) (Ryvolova, et al., 2011). Mass spectrometry 
[electrospray ionization (ESI), matrix assisted laser desorption-ionization (MALDI) and 
inductively coupled plasma (ICP) ionization techniques] represents the most advanced 
method in metallomics. These techniques provide essential information about protein identity 
and structure (ESI, MALDI), and elemental composition (ICP). It has to be also noted that 
some MS-based studies have succeeded in identifying MT (sub)isoforms in human cells either 
based on tryptic digests (Alvarez, et al., 2012; Shabb, Muhonen, & Mehus, 2017; Wang, et 
al., 2007), or on unique masses of intact isoforms (Mounicou, et al., 2010; Wang, et al., 
2007). Moreover, MALDI imaging allows for studying of proteins distribution in paraffin-
embedded tissue slices or cryosections analogical to histology, with the advantage of 
detection of multiple or unknown analytes without labelling (Arentz, et al., 2017; Norris & 
Caprioli, 2013; Panderi, et al., 2017; Rodrigo, et al., 2014).  
 
MTs can regulate and be distinctly regulated by a number of biological processes 
MTs are involved in regulation of numerous processes, among others, cell proliferation and 
apoptosis and several aspects of the carcinogenesis or inflammation (Theocharis, Margeli, 















their protein-protein interactions, metal binding and antioxidant properties. The target proteins 
for interaction belong to transcription and growth factors, cytokines, extracellular matrix 
degrading enzymes, apoptosis regulators, stress proteins related to oxidative and radiation 
damage. Transcription factors such as p53 protein, nuclear factor–κB (NF-κB), esophageal 
cancer-related gene 4 (ECRG4), specificity protein 1 (Sp1), transcription factor IIIA (TFIIIA), 
estrogen receptor (ER), Gal4 and tramrack (TTK) interact with MTs and change their 
function. MTs are also source of zinc or copper and therefore activators of various 
metalloenzymes, for example matrix metalloproteinases (MMP), carbonic anhydrase, alkaline 
phosphatase (AP), δ-aminolevulinic acid dehydratase, or superoxide dismutase (SOD). 
Interaction with MTs was documented also at endocytic low-density lipoprotein receptors 
(LDLRs), especially megalin and lipoprotein receptor related protein 1 (LRP1) (Krizkova, et 
al., 2012; Zalewska, Trefon, & Milnerowicz, 2014).  
Although MTs show increased expression in various tumours (breast, kidney, lung, 
nasopharynx, ovary, salivary gland, testes, thyroid and bladder cancers, in certain 
malignancies such as hepatocellular carcinoma, prostate and colorectal cancer, their down-
regulation has been evidenced (Gumulec, Raudenska, Adam, Kizek, & Masarik, 2014; S. 
Takahashi, 2015). Kanda et al. have suggested that the mechanisms of MT-1G silencing were 
related to promoter hypermethylation (Kanda, et al., 2009). Furthermore, representative 
primary gastric cancer having no expression of MT-3-encoding mRNA demonstrated 
hypermethylation of the MT-3 intron l CpG island (Deng, et al., 2003). The methylated and 
unmethylated MT-1 promoters are differentially regulated by DNA methyltransferase and 
methyl-CpG binding proteins, and the suppression of MT promoters by DNA 
methyltransferase is independent of its enzymatic function (Majumder, et al., 2006). DNA 
methylation plays an important role in cancer formation by silencing tumour suppressor 















be also connected with mutation of tumour suppressor genes (Cherian, Jayasurya, & Bay, 
2003). In TP53 mutated cell lines MT was not induced and apoptosis was not initiated after 
the addition of cadmium or copper (Fan & Cherian, 2002). Epigenetic inactivation of XAF1 
tumour suppressor gene is frequently observed in multiple human cancers. Shin et al. 
presented evidence that XAF1 plays a critical role in cell-fate decisions under heavy metal 
induced stress conditions through the mutual antagonism with MT-2A. XAF1 is activated as a 
transcription target of MTF-1 and destabilizes MT-2A through the interaction-directed 
lysosomal degradation, whereas it is destabilized by MT-2A under cytostatic stress 
conditions. XAF1-mediated MT-2A inactivation leads to elevation of free intracellular zinc 
level and up- and down-regulates proteins p53 and XIAP, respectively, to promote apoptosis 
(Shin, et al., 2017). 
MT polymorphisms may increase or decrease the expression efficiency of genes. Highly 
statistically significant associations were detected between single-nucleotide polymorphisms 
in core promoter region of MT and Cd, Zn, Cu and Pb levels in prostate cancer tissue 
(Krzeslak, et al., 2013). MTs are transcriptionally regulated in response to metal ions. A key 
protein in this process is metal-regulatory factor 1 (MTF1), which binds metal responsive 
elements located upstream of MT genes. Thus, genetic variation in MTF1 may modulate 
expression of MT and thereby influence biological management of metals (Adams, et al., 
2015). 
Connection between epigenetics and MTs regulation human carcinogenesis 
Epigenetics, originally defined by C. H. Waddington (Waddington, 1942) as ‘the causal 
interactions between genes and their products, which bring the phenotype into 
being’, involves understanding chromatin structure and its impact on gene functions. The 
information conveyed by epigenetic alterations plays a crucial role in all DNA-based 















malignant diseases (Dawson & Kouzarides, 2012). As MTs play an important role in many 
types for solid tumours and leukemias, the significance of epigenetic modifications of MT 
genes in cancer cells merits discussion. 
 
Epigenetic alterations due to DNA methylation processes  
Genome-wide analyses have shown that DNA methylation is found in long stretches of 
chromosome regions containing clusters of contiguous CpG islands or gene families. 
Hypermethylation of various gene clusters has been reported in many cancer types (Esteller, 
2007) (Jadhav, et al., 2015). Several studies, which have performed methylation analyses, 
identified de novo hypermethylation of MT promoters associated with consequent MTs 
silencing. In that way, Jadhav and colleagues revealed that methylation contributes to 
repression of MT-1 gene cluster in breast cancer, irrespective of oestrogen receptor (ER) 
status (Jadhav, et al., 2015). Noteworthy, they also revealed a negative correlation between 
invasiveness of ERα+ cells (MCF-7) and MT-1F and MT-1M expression, which thus may 
play an anti-oncogenic role. Distinct role was identified for MT-3, which is commonly 
silenced in normal breast tissue and breast-derived cell lines, but can be found in breast 
cancers tending to poor disease outcome (Gomulkiewicz, et al., 2016; Kmiecik, et al., 2015; 
Zeisig, Koklic, Wiesner, Fichtner, & Sentjurc, 2007). Interestingly, Somji et al. revealed that 
treatment of non-tumorigenic MCF-10A cells with demethylation agent Decitabine or histone 
deacetylase inhibitor, Entinostat, restored the expression of MT-3 (Somji, et al., 2010), 
suggesting its epigenetic regulation. Comparable phenomenon has been also observed in 
endometrial cancer cells, in which demethylation agent Azacytidine reactivates expression of 
MT-1E (Tse, et al., 2009). Moreover, it was found that promoter of MT-1E was 
hypermethylated in more than 42% of endometrial carcinoma specimens, but not in normal or 















It is worth noting that epigenetic regulation can act in a location-specific manner. Peng and 
co-workers have shown that oesophageal carcinomas display high rate of methylation of CpG 
of MT-3 from -372 to -306 from the transcription start site, which was not found in benign 
specimens (D. F. Peng, et al., 2011). Moreover, they identified a significant correlation 
between hypermethylation of -127 to -8 CpG sites with advanced tumour stages and lymph 
node metastases. Deliberately, we do not mention all studies, as they demonstrate similar 
results (MT-1F in colon cancer, MT-1 in rat hepatoma, MT-2A in gastric cancer, MT-1M and 
MT-1G in hepatocellular carcinoma or MT-1G in thyroid cancer (J. Fu, et al., 2013; Ghoshal, 
Majumder, Li, Dong, & Jacob, 2000; Ji, et al., 2014; Pan, et al., 2016; Yan, et al., 2012)), but 
overall, it is evident that hypermethylation of specific regions in CpG islands of selected MT 
genes could be a valuable diagnostic and prognostic marker, warranting further investigation.  
One may ask why these events occur. Several factors mechanistically linked with altered 
methylation have already been identified. During aging a large overlap among 
hypermethylated genes and tumorigenesis has been identified, and is thus considered as one 
of the important factors (Klutstein, Nejman, Greenfield, & Cedar, 2016; Kwabi-Addo, et al., 
2010; Teschendorff, et al., 2010). Clear molecular links with aberrant DNA methylation were 
found also for exposures to chemical agents (Hutt, et al., 2005) or inflammatory processes 
caused by Helicobacter pylori or hepatitis B virus (J. Liu, et al., 2006; Niwa, et al., 2010; Su, 
et al., 2007). Despite that there is still a lack of studies showing the straight links between 
specific exposures and aberrant methylation of MTs genes, which could bring novel insights 
into carcinogenic processes. 
 
Role of microRNA (miRNA) in post-transcriptional regulation of MTs 
MiRNA belong to a class of short (18-25 nucleotides) noncoding RNAs, involved in RNA 















Meltzer, & Shimizu, 2011), contributing to physiological and pathophysiological functions 
including carcinogenesis (Lu, et al., 2005). Although miRNAs were discovered in 1993 (R. C. 
Lee, Feinbaum, & Ambros, 1993) and till that time it has been intensively investigated, only 
little is known about relation between miRNA and MTs regulation. 
Zhang and co-workers revealed that miR-1246 and miR-1290 are significantly enriched in 
tumour-initiating cells and play a critical role in regulation of tumour growth and metastasis, 
particularly through repressing the MT-1G (Zhang, et al., 2016). In gastric cancer, MT-2A 
was found to be a potential target of miR-23a (An, et al., 2013). A significant inverse 
correlation between expression of miR-23a and MT-2A was detected in 70% of tumour 
samples and furthermore, overexpression of miR-23a also greatly reduced both MT-2A 
protein and mRNA expression levels in gastric epithelial (GES1) cells. Similarly, we have 
identified negative inverse correlation between miR-376 and MT-2A in malignant prostate 
cells (22Rv1) and miR-224 and MT-1A in metastatic prostate (PC-3) cells. It is worth noting 
that miRNAs obviously directly regulates specific genes encoding MTs (sub)isoforms, 
however further research might be done to fully understand this phenomenon (An, et al., 
2013). 
  
Regulation and expression of MTs (sub)isoforms is distinct across various types of 
malignant diseases 
Complex role of MTs in cancer  
Numerous immunohistochemical and gene expression studies have demonstrated that changes 
in MTs expression are associated with the process of carcinogenesis in various types of 
human malignancies, or are even associated with a more aggressive phenotype and 
therapeutic resistance, ultimately resulting in a worse prognosis (Gumulec, et al., 2014; 















the change in MT-1/2 protein expression may differ from the change in the expression of 
single MT isoforms. For instance, MT-1/2 over-expression has been found in cutaneous 
malignant melanomas in association with poor prognosis (Emri, et al., 2013; Sugita, 
Yamamoto, & Asahi, 2001; Weinlich, 2009), but it has also been demonstrated that epigenetic 
down-regulation of MT-1E and MT-1G isoforms might play a role in melanoma progression 
(Faller, et al., 2010; Koga, et al., 2009). Most likely, some MT isoforms have specific 
functions in the cells, but the exact mechanisms behind these phenomena remain still unclear. 
Interestingly, meta-analysis of independent microarray datasets revealed that expression of an 
inhibitor of apoptosis (BIRC5) and certain MT isoforms (MT-1B, -1E, -1F, -1H, -1X) 
clustered in various cancers showing a high interconnection between these genes (Choi, Yu, 
Yoo, & Kim, 2005). Nevertheless, MT isoform expression pattern in a cancer might reflect 
the tissue type, differentiation status, proliferative index, the level of inflammation, and 
perhaps the carcinogenic stimuli and signalling pathways implicated in tumour development 
(Hanada, Sawamura, Hashimoto, Kida, & Naganuma, 1998; Cherian, et al., 2003). 
Exploration of changes in expression of particular MT isoforms in various cancers can 
contribute to better understanding of the process of carcinogenesis and identification of novel 
therapeutic targets. 
To this date numerous studies aiming on MTs in cancer, both in human tumour tissues and 
cell lines, have been published providing an extensive pool of data. To provide a 
comprehensive insight into the complicated relation between MTs and cancer, the results 
showing expression of MTs and their pseudogenes in various tumour tissues are summarized 
in Table 2, while the overall summary of results obtained from cell cultures in vitro are 
summarized in Tables 3 – 10. As it is obvious from the presented tables, the most data 




















upon metals treatment, as well as it is not within single cell lines even those derived from the 
same cancer type. The similar trend is seen for other treatments with other metals and 
cytostatics or inhibitors of cellular processes, natural compounds and/or nanoparticles. Other 
important fields of studies are focused on regulation of MT genes and studies of cancer-
related conditions such as chemoresistance, DNA mutations, RNA interference and hypoxia. 
The most of work for MT-1 (sub)isoforms and MT-4 isoform has been done using nucleic 
acids-based methods due to the lack of reliable antibodies. On the other hand, expression of 
MT-2A and MT-3 were also studied using immuno-based assays. Overall, based on the data it 
should be stated that due to the variability of MTs within various tumour types and 
conditions, a number of MT genes can be identified, whose expression exhibits tumour-related 
functions, and thus their modulation can reverse the tumour progression. In next sub-chapters 
we will describe the most notable findings regarding the MTs (sub)isoforms and specific 
types of malignant diseases. 
 
Prostate cancer 
Reduced MT-1/2 protein expression was reported in tissues derived from prostate cancer as 
compared with benign prostatic hyperplasia (J. D. Lee, Wu, Lu, Yang, & Jeng, 2009), 
however, in other studies, an increased expression of MT-1/2 and MT-3 has been found in 
prostate cancer, even it was shown to correlate with the histological grade of neoplasm 
(Albrecht, et al., 2008; El Sharkawy, Abbas, Badawi, & El Shaer, 2006; Garrett, Sens, et al., 
1999). A recent study on 128 patients with prostate cancer demonstrated that high expression 
of MT-2A protein in cancer cells is associated with a decreased biochemical recurrence-free 
survival rate (Ma, et al., 2015). The -5 A/G single nucleotide polymorphism (SNP; 
rs28366003) in core promoter region of MT-2A is able to affect the expression of the MT-2A 















carriers, heterozygosity for the G variant is coupled with a significantly increased risk of 
prostate cancer in a Polish population (Forma, et al., 2012). The expression of MT-2A seems 
to negatively correlate with Cu, Pb and Ni concentrations in prostate cancer tissues (Krzeslak, 
et al., 2013). While MT-1A, MT-1E, MT-2A, and MT-3 expressions have been shown in both 
healthy prostatic tissue and prostate cancer, the expression of MT-1X gene could only be 
detected in normal prostate (Garrett, et al., 2000; Garrett, Sens, et al., 1999). Down-regulation 
of MT-1G by promoter hypermethylation was demonstrated in 29 (24%) of 121 prostate 
cancer, 5 (13%) of 39 high-grade prostatic intraepithelial neoplasms, 3 (10%) of 29 benign 
prostatic hyperplasia, and 0 (0%) of 13 normal prostate tissue samples without significant 
differences in methylation frequencies or levels (Henrique, et al., 2005). Methylation levels 
were found to correlate with tumour stage and were more frequent in prostate cancer that 
spread beyond the prostate capsule (Henrique, et al., 2005). Low expression of MT-1H due to 
promoter hypermethylation has been described in prostate cancer with poor prognosis (Han, et 
al., 2013). In a microRNA microarray study on 50 prostate adenocarcinomas with and without 
perineural invasion, miR-224 has been identified as the most differently expressed microRNA 
(Prueitt, et al., 2008). This microRNA has been shown to be expressed by perineural cancer 
cells and to down-regulate MT expression in these cells (Prueitt, et al., 2008). For summary of 
MTs (sub)isoforms expression studies in human prostate cancer cell lines see Table 3. 
 
Lung cancer 
Increased MT-1/2 protein expression has been demonstrated in 62 (89.9%, n=69) non-small 
cell lung cancer (NSCLC) samples as compared to non-malignant lung tissues (NMLT, n=12) 
(Werynska, Pula, Muszczynska-Bernhard, Gomulkiewicz, Piotrowska, et al., 2013). 
Expression of MT-1B, -1F, -1G, -1H and -1X genes were found to be significantly up-















(Werynska, Pula, Muszczynska-Bernhard, Gomulkiewicz, Piotrowska, et al., 2013). Higher 
MT-1B mRNA expression was associated with squamocellular and adenocarcinoma subtype 
of NSCLC (Werynska, Pula, Muszczynska-Bernhard, Gomulkiewicz, Piotrowska, et al., 
2013), where a review of studies on MT expression in human lung cancer cell lines is shown 
in Table 4. Higher MT-1F mRNA expression was associated with larger primary tumour size, 
with higher grade of malignancy and poor patients' survival (Werynska, Pula, Muszczynska-
Bernhard, Gomulkiewicz, Piotrowska, et al., 2013). In this study, statistically insignificant 
higher MT-1A mRNA expression was also detected in larger primary tumours, as well as up-
regulated MT-2A mRNA that predicted poor prognosis (Werynska, Pula, Muszczynska-
Bernhard, Gomulkiewicz, Piotrowska, et al., 2013). In another study, the level of MT-1A, 
MT-2A, and MTF-1 expression have been shown to be even lower in lung cancer specimens 
compared to cancer-surrounding tissues (Liang, et al., 2013). Importantly, MT-1X was 
identified as metastasis related gene in NSCLC cell lines in a very recent study (Y. Liu, et al., 
2016). Comparing the expression level of MT-1X in human lung cancer tissues and matched 
adjacent normal lung tissues, a significant difference could be shown between stages I and IV 
confirming the prognostic value of MT-1X gene expression in clinical settings (Y. Liu, et al., 
2016). Five SNPs in the MT-1 gene region have been found to be associated with increased 
risk of lung cancer among non-heavy smokers in a Japanese population (rs7196890 showed 
the strongest association) and the impact of the polymorphisms decreased with the increasing 
consumption of cigarettes (Nakane, et al., 2015). Expression of MT-3 has also been 
investigated in lung cancer, and was found to be significantly up-regulated in NSCLC as 
compared to NMLT (Werynska, Pula, Muszczynska-Bernhard, Gomulkiewicz, Jethon, et al., 
2013). In addition, compared with NMLT, higher nuclear, but lower cytoplasmic MT-3 
expression could be detected in cancer cells (Werynska, Pula, Muszczynska-Bernhard, 















larger primary tumour size, nevertheless, lower nuclear MT-3 expression was linked with 
higher tumour grade, and lower MT-3 mRNA expression seemed to be associated with poor 
patient outcome (Werynska, Pula, Muszczynska-Bernhard, Gomulkiewicz, Jethon, et al., 
2013). From the epigenetic point of view, an overall increase in gene promoter methylation 
has been reported in association with age and environmental exposure in NMLT (Tsou, et al., 
2007). Furthermore, an association between methylation status of MT genes and gender, 
histology, asbestos exposure, and lymph node involvement was demonstrated in patients with 
malignant mesothelioma (Tsou, et al., 2007).  
 
Breast cancer 
Disequilibrium in zinc homeostasis and high concentration of zinc in breast cancer tissues has 
been reported (Chandler, et al., 2016). The increased MT gene expression can frequently be 
detected in breast tumour specimens with predominantly cytoplasmic MT protein expression 
(see Table 5 for a review of studies on MT expression in human breast cancer cell lines), and 
it correlates with higher histological grade and significantly lower recurrence-free survival 
after treatment with adjuvant chemotherapy, but seems to be independent of age, tumour size 
and oestrogen receptor (OR) status (Yap, et al., 2009). MT-1A, MT-1E, MT-1F, MT-1G, MT-
1H, MT-1X and MT-2A but not MT-1B mRNA was detected in invasive ductal breast cancer 
tissue (IDBC) samples (R. X. Jin, et al., 2002). MT-2A, MT-1E, MT-1F were found to be 
expressed in both IDBC specimens and their adjacent benign breast tissues, although MT-1F 
expression seemed to be significantly higher in benign breast tissues compared with the breast 
cancers; MT-2A was demonstrated as the predominant isoform in both benign and malignant 
breast tissues (R. X. Jin, Bay, Chow, Tan, & Dheen, 2001; R. X. Jin, et al., 2002). In another 
study, higher MT-1F mRNA expression was found to be associated with higher histological 















protein expression were found to be in association with cancer cell proliferation (Ki-67 
immunolabelling) and histological grade (R. X. Jin, et al., 2002). In case-control studies, 
SNPs in MT-2A (rs1580833 in a German population and rs28366003 in a Polish population) 
showed a positive association with breast cancer risk (Krzeslak, et al., 2014; Seibold, et al., 
2011). In further study, significantly higher MT-1E mRNA expression was detected in OR-
negative breast tumour tissues specimens compared to OR-positive ones (R. Jin, Bay, Chow, 
Tan, & Lin, 2000). Nevertheless, epigenetic repression of MT-1 gene cluster was also 
demonstrated in breast cancer (Jadhav, et al., 2015). In silico analysis revealed much lower 
gene expression of this cluster in The Cancer Genome Atlas cohort for OR-positive tumours 
(Jadhav, et al., 2015). Comparing the methylation of CpG islands in tissues (tumour, healthy 
breast and blood) from patients with breast cancer revealed that the promoter of MT-1A was 
methylated above 25% in 18 primary and metastatic tumours, but there was also >10% 
methylation of healthy breast tissue in 5 samples suggesting that the methylation process for 
this gene takes place already in normal breast cells (Piotrowski, et al., 2006). Interestingly, 
metal induced MT gene expression also seems to be dependent on epigenetic regulation in 
breast cancer cells, namely on the histone acetylation status of the gene promoter, which is 
determined by p53 function (Ostrakhovitch, Olsson, von Hofsten, & Cherian, 2007). In the 
presence of mutated p53 the expression of MT-1A and MT-2A is dampened in response to 
metal, but constitutive MT-3 gene expression is allowed (Ostrakhovitch, Song, & Cherian, 
2016). Sens et al. showed that MT-3 over-expression was detected in breast cancer samples, 
and it was found to be associated with high recurrence rate (Sens, et al., 2001). In another 
study, however, MT-3 expression has been found to be lower in IDBC specimens compared 
with non-malignant breast tissues or mastopathies, in addition, the level of MT-3 mRNA was 
demonstrated to be even lower in breast cancers with lymph node metastasis than in 

















The down-regulation of MT-1/2 expression was revealed in association with colorectal cancer 
progression, although a relatively high MT content could be detected in colorectal cancers 
with very poor prognosis (Arriaga, et al., 2012; Janssen, et al., 2000). A review of studies on 
MT expression in colorectal cancer cell lines is shown in Table 6. Down-regulation of MT-1B 
(Jansova, et al., 2006), -1E (Arriaga, et al., 2012), -1F (Arriaga, et al., 2012; Jansova, et al., 
2006; Yan, et al., 2012), -1G (Arriaga, et al., 2012; Jansova, et al., 2006; Yan, et al., 2012), -
1H (Arriaga, et al., 2012; Jansova, et al., 2006), -1M (Arriaga, et al., 2012), -1X (Yan, et al., 
2012), and MT-2A (Jansova, et al., 2006; Yan, et al., 2012) has been demonstrated during the 
transition from normal mucosa to cancer, the less down-regulated expression of MT-1X and 
MT-2A was thought to support MT protein expression in tumour tissue (Arriaga, et al., 2012). 
Radiotherapy seems to be able to induce the expression of MT-1F, MT-1X and MT-2A genes 
in rectal cancer tissue, however, there is no difference in MT-1/2 protein expression levels 
between the samples obtained before and after radiotherapy (Szelachowska, et al., 2012). 
Regarding the mechanism of down-regulation of gene expression, promoter hypermethylation 
of MT-1G (Arriaga, et al., 2012), and loss of heterozygosity at the MT-1F locus (Yan, et al., 
2012) have been also identified. Noteworthy, in high microsatellite instability colorectal 
carcinoma tissues MT-1X T20 (3'UTR, T20 mononucleotide repeat of the MT-1X gene) 
instability can be more frequently detected as compared to microsatellite stable or low 
microsatellite instability colorectal cancer cases (97.3% sensitivity and 100% specificity) 
(Morandi, et al., 2012). Serine peptidase inhibitor, Kazal type 1 (SPINK1) that has been 
shown to contribute to increased cell proliferation, invasion, soft agar colony formation, and 
therapy resistance in colon adenocarcinoma cell culture through activation of oncogenic 















isoforms in colon cancer cells as SPINK1 knockdown leads to up-regulation of MT-1B, -1E, -
1G, -1H, -1L, -1M, -1X, and MT-2A genes in these cells (Tiwari, et al., 2015). 
 
Hepatocellular carcinoma  
Compared to the adjacent non-malignant liver, significant repression of MT-1G and MT-1M 
due to promoter hypermethylation has been demonstrated in primary hepatocellular 
carcinomas (K. Y. Y. Chan, et al., 2006; Kanda, et al., 2009; J. Mao, et al., 2012). A recent 
study confirmed that low MT-1M expression correlates with high alpha-fetoprotein levels and 
early (<24 months) tumour recurrence after surgery (Ding & Lu, 2016). Furthermore, the 
methylation status of MT-1G and MT-1M promoters detected in serum cell free DNA (liquid 
biopsy) in patients with hepatocellular carcinoma was also shown to be significantly higher 
than that in patients with chronic hepatitis B or in normal controls (Ji, et al., 2014). In 
addition, in carcinoma patients associations have been found between serum MT-1M 
promoter methylation and tumour size, and between simultaneous MT-1G and MT-1M 
promoter methylation and higher incidence of vascular invasion or metastasis, respectively 
(Ji, et al., 2014). Association between hypermethylation of the promoter region of MT-1H and 
liver cancer with poor clinical outcome has also been reported (Han, et al., 2013). Increased 
activity of DNA methyltransferase 1 (Dnmt1) might be one of the reasons responsible for 
down-regulation of MT gene expression in liver cancer (Takata, et al., 2013). Dnmt1 is a 
direct target of miR-140, and reduced expression of the microRNA-containing 
ribonucleoprotein complex component DDX20, which is frequently seen in hepatocellular 
carcinomas, can lead to the impairment of miR-140 function (Takata, et al., 2013). MT-1M is 
also a target gene of miR-24-3p that is another significantly up-regulated microRNA in liver 
cancer tissues as compared with non-tumour liver tissues (Dong, et al., 2016). Furthermore, 















CCAAT/enhancer binding protein alpha (C/EBPalpha) in liver cells (Datta, et al., 2007). In 
hepatocellular carcinoma the phosphorylation of C/EBPalpha is decreased due to suppressed 
activity of glycogen synthase kinase-3, a downstream effector of PI3K/AKT signalling 
pathway (Datta, et al., 2007). In a hospital-based case-control study it has been revealed that 
MT-1 rs8052394, rs964372, and rs8052334 A-G-T haplotype can enhance the carcinogenic 
effect of smoking on liver, and carriers with this haplotype have higher risk for liver cancer 
development than the control group (A-C-T, the most common haplotype) (Wong, et al., 
2013). Decreased expression of MT-1A, -1E, -1F, -1G, -1H, -1X genes was demonstrated in 
intrahepatic cholangiocarcinoma tissue samples as compared with normal liver tissues in 
patients residing in Northeast Thailand, a region with a high prevalence of liver fluke 
infection (Subrungruang, et al., 2013). Table 7 summarizes studies on expression of MT in 
hepatic cancer cell lines. 
 
Head and neck cancer 
Significantly higher MT-1/2 expression was observed in oral squamous cell carcinoma tissues 
comparing with oral leukoplakia or normal epithelial tissue samples (Pontes, et al., 2009). 
Nevertheless, up-regulation of MT-1F gene expression, but down-regulation of MT-1A, MT-
1X, MT-3 and MT-4 gene expressions was detected in carcinoma tissue specimens compared 
with non-neoplastic oral mucosa (Brazao-Silva, et al., 2015). High MT-1X expression in 
cancer tissues was restricted to non-metastatic cases, but high MT-3 expression was 
associated with increased risk of lymph node metastasis (Brazao-Silva, et al., 2015). 
Furthermore, the low level of MT-1G mRNA in carcinoma tissues correlated with poor 
prognosis (Brazao-Silva, et al., 2015). An SNP analysis revealed that MT-1 rs11076161 AA, 
rs964372 CC, and rs7191779 GC genotypes are protective against oral squamous cell 















development (Zavras, Yoon, Chen, Lin, & Yang, 2011). Regarding squamous cell laryngeal 
cancer, the -5 A/G (rs28366003) SNP in the core promoter region of the MT-2A has been 
shown to be related to the higher cancer risk (Starska, Krzeslak, Forma, Olszewski, Lewy-
Trenda, et al., 2014). Moreover, the most carriers of minor allele had a higher stage, increased 
cancer aggressiveness, as defined by a higher total tumour front grading score and diffuse 
tumour growth (Starska, Krzeslak, Forma, Olszewski, Lewy-Trenda, et al., 2014). In further 
study, a significant association between the rs28366003 SNP in the MT-2A gene and MT-2A 
mRNA levels was demonstrated in squamous cell laryngeal cancer and non-cancerous 
laryngeal mucosa samples, and an inverse relation was shown between MT-2A expression 
and Cd, Zn and Cu content in tissues (Starska, Krzeslak, Forma, Olszewski, Morawiec-
Sztandera, et al., 2014). Table 8 summarizes studies on expression of MT in head and neck 
cancer cell lines. 
 
Oesophageal cancer 
Down-regulation of MT-1G, -1M, and MT-3 gene expressions have been detected in 
oesophageal squamous cell carcinoma tissue samples as compared with non-malignant 
oesophageal tissues (Kumar, Chatopadhyay, Raziuddin, & Ralhan, 2007; Y. C. Lee, et al., 
2011; Oka, et al., 2009; E. Smith, et al., 2005). Importantly, methylation study on tissue 
specimens from normal oesophageal mucosae from healthy subjects without carcinogen 
exposure, normal mucosae from healthy subjects with carcinogen exposure, normal mucosae 
from cancer patients, and in cancerous mucosae has revealed significantly higher methylation 
of MT-1M in cancer samples, and in addition, in drinkers and in smokers (Y. C. Lee, et al., 
2011; Oka, et al., 2009). Down-regulation of MT-3 gene expression in oesophageal squamous 
cell carcinoma seems also to be associated with promoter hypermethylation (E. Smith, et al., 















oesophageal adenocarcinomas has revealed that in tumour tissues the CpG nucleotides in two 
regions (from 2139 to -49 and +296 to +344) were significantly hypermethylated as compared 
to normal samples, whereas CpG nucleotides from -372 to -306 from the transcription start 
site were highly methylated in both tumour and normal samples (D. F. Peng, et al., 2011). 
Furthermore, the DNA hypermethylation from 2127 to 28 CpG sites was found to be 
associated with advanced cancer and lymph node metastasis (D. F. Peng, et al., 2011). 
Recently, up-regulation of the expression of a long non-coding RNA, HNF1A-AS1, has been 
demonstrated in oesophageal adenocarcinomas relative to their corresponding normal 
oesophageal tissues, and MT-1E was identified as its downstream target (X. Yang, et al., 
2014). 
 
Tumours of central nervous system 
Gene expression studies on glioblastoma tumour specimens revealed an association between 
high MT-1A, -1B, -1E, -1F, -1H, and MT-3  expression and poor patient survival (Mehrian-
Shai, et al., 2015). Moreover, MT-2 protein expression was found to be significantly higher in 
glioblastoma multiforme tissue samples from the first surgery than in tumour's fragments of 
the same region but obtained 1 year apart suggesting a dynamic change in MT gene 
expression with progression in this type of cancer (de Aquino, et al., 2016). Very recently, 
down-regulation of miR-340 and up-regulation of miR-1293 has been shown in glioblastoma 
multiforme biopsies (Cosset, et al., 2016). Interestingly, several MT genes (MT-1A, -1E, -1F, -
1H, -1X, -2A) were identified as targets of these microRNAs, but it was emphasised that the 
induced changes in gene expression is influenced by the cellular micro-environment (Cosset, 
et al., 2016). Down-regulation of MT genes (MT-1L, MT-1G, MT-1E, MT-1X, MT-1B, MT-2A, 
and MT-3) has been demonstrated as a common event at relapse of ependymoma, however, 















Methylation of the promoter of MT-3 gene has been supposed, but could not be proved 
(Peyre, et al., 2010). 
 
Thyroid cancer 
Although the up-regulation of MT expression in follicular thyroid carcinoma has been 
reported in one study (Back, et al., 2013), several data have been published to demonstrate the 
down-regulation of MT expression in thyroid cancers (both in papillary and follicular thyroid 
carcinoma, but to a greater extent in papillary carcinoma) compared to normal thyroid tissue 
(Ferrario, et al., 2008; J. Fu, et al., 2013; Huang, De La Chapelle, & Pellegata, 2003). It has 
been demonstrated that promoter methylation contributes to MT-1G inactivation in thyroid 
cancers, even an association between MT-1G hypermethylation and lymph node metastasis in 
papillary thyroid cancer patients has been found (J. Fu, et al., 2013; Huang, et al., 2003). Loss 
of heterozygosity seems to be a remarkably rare mechanism of loss of MT-1G gene function 
in this cancer (Huang, et al., 2003). 
 
Renal cancer 
MT protein expression has been demonstrated in specimens from renal cell carcinoma (RCC) 
and it was found to be associated with significantly worse prognosis (Nguyen, et al., 2000; 
Tuzel, Kirkali, Yorukoglu, Mungan, & Sade, 2001). However, down-regulation of MT-1H 
(Alkamal, et al., 2015; Nguyen, et al., 2000; M. Takahashi, et al., 2001), MT-1G (Alkamal, et 
al., 2015; M. Takahashi, et al., 2001), MT-2A (Alkamal, et al., 2015), MT-1A, MT-1L and 
MT-1E (M. Takahashi, et al., 2001) have been shown in RCC. In one study, comparing cancer 
tissue samples to non-malignant tissues from 11 patients with RCC the same level of MT-1E, 
MT-1F and MT-1X expression, but up-regulation of MT-2A and down-regulation of MT-1A 

















Lower MT-2A mRNA and protein expression has been detected in gastric cancer tissue 
samples comparing with the adjacent normal gastric tissues (J. M. Kim, et al., 2005; Pan, 
Xing, Cui, Li, & Lu, 2013). In addition, loss of MT-2A expression in gastric cancer seems to 
be associated with down-regulation of I kappa B-alpha expression, diffuse- and intestinal-type 
histological subtypes, higher grade, and an advanced clinical stage (Pan, Huang, et al., 2013; 
Pan, Xing, et al., 2013). MT-2A is a potential target of miR-23a, and comparing gastric cancer 
tissue specimens to matched normal tissues an increase in miR-23a expression has been 
detected and an inverse correlation was found between miR-23a and MT-2A expression (An, 
et al., 2013). Nevertheless, expression of MT-2A can be induced by chemotherapy, and high 
MT-2A expression in gastric cancer tissue is associated with better response to chemotherapy 
and prolonged patient survival as compared to those with low MT-2A expression (Pan, et al., 
2016). Furthermore, it seems to be possible to induce the up-regulation of MT-2A expression 
by inhibition of histone deacetylase activity in gastric cancer cells (Pan, et al., 2016). Down-
regulation of MT-3 gene expression by hypermethylation has also been found in gastric 
cancers, particularly in p53-negative cases (Deng, et al., 2003). 
 
Bladder cancer 
MT-1/2 protein over-expression has been demonstrated in bladder cancer tissues, whereas 
MT-1/2 expression could not be detected in non-malignant bladder specimens (Somji, Sens, 
Lamm, Garrett, & Sens, 2001). In bladder cancer patients a high MT expression in tumour 
tissues was linked to shorter tumour-specific survival, and increased recurrence rates (Hinkel, 
Schmidtchen, Palisaar, Noldus, & Pannek, 2008). Expression of mRNA for the MT-2A and 















MT-1E was found to be variable, while expression of MT-1X proved to be up-regulated in 
cancer as compared to the level of MT-1X mRNA in normal bladder tissue (Somji, et al., 
2001). In another cohort of patients with bladder cancer the expression of MT-1E has been 
found to be associated with higher cancer stage (Wu, Siadaty, Berens, Hampton, & 
Theodorescu, 2008). Using loss of function analysis, the same research group demonstrated 
that MT-1E expression contributes to cancer cell migration (Wu, et al., 2008). MT-3 protein 
expression seems to occur frequently in carcinoma in situ as well as in low- and high-grade 
urothelial cancer (Somji, et al., 2011; Zhou, et al., 2006). In contrast, MT-3 gene is silenced in 
non-transformed urothelial cells by a mechanism involving histone modification of the MT-3 
promoter (Somji, et al., 2011). 
 
Endometrium cancer 
Loss of MT expression in association with copy number changes has been found to be an 
early event in development of uterine corpus endometrial carcinoma, and it was found to be 
associated with poorer prognosis (Delaney & Stupack, 2016). Down-regulation of MT-1E 
gene expression due to promoter hypermethylation could be demonstrated in carcinoma tissue 
samples, particularly with low OR-alpha expression, as compared with normal endometrial 
tissues or hyperplasias (Tse, et al., 2009). 
 
Ovarian cancer 
Down-regulation of MT-1L, -1X, and MT-2A gene expression could be revealed in ovarian 
tissues reflective of low malignant potential/early cancer onset and possible pre-malignant 
stages (Mougeot, et al., 2006). However, the absence of MT protein expression in ovarian 
cancer samples correlated with improved progression-free survival in patients treated with 

















High MT protein expression was detected in pancreas adenocarcinoma tissues compared with 
pancreatic serous cystadenoma or healthy pancreatic tissue samples (Sliwinska-Mosson, 
Milnerowicz, Rabczynski, & Milnerowicz, 2009). 
 
Sarcoma and other mesenchymal tumours 
Up-regulation of MT-1B, -1E, -1G, -1H, -1L, -1X, and MT-2A gene expression was found in 
osteosarcoma tissue samples compared with bone biopsies of non-malignant lesions, and three 
MT isoforms (MT-1E, -1H and MT-1X) were among the 10 most highly up-regulated genes in 
the osteosarcoma transcriptome  (Endo-Munoz, Cumming, Sommerville, Dickinson, & 
Saunders, 2010). An association between MT-1F, -1H, -1X, and MT-2A over-expression in 
tumour specimens and high metastasis risk has also been observed in patients with high-grade 
soft tissue sarcoma (Skubitz, Francis, Skubitz, Luo, & Nilbert, 2012). As mentioned above, 
the down-regulation of MT-2A expression is a frequent finding in gastric cancer tissues 
compared to adjacent normal tissue samples (J. M. Kim, et al., 2005; Pan, Xing, et al., 2013). 
Interestingly, comparing MT-2A expression in tissue specimens of gastrointestinal stromal 
tumour (GIST) located in the stomach with that in early gastric carcinomas, significantly 
lower MT-2A mRNA expression and nuclear MT protein expression were found in GIST 
samples  (Soo, et al., 2011). 
 
Haematological malignancies 
Up-regulation of MT gene expression has been demonstrated in diffuse large B-cell 
lymphoma (DLBCL) with poor prognosis, including activated B-cell and type-3 DLBCL 















germinal center DLBCL (Poulsen, et al., 2006). Down-regulation of MT-3 gene expression 
due to promoter methylation has been detected in paediatric acute myeloid leukaemia samples 
(Y. F. Tao, et al., 2014). Table 9 summarizes studies on expression of MT in human 
haematological cancer cell lines. 
 
Melanoma and non-melanoma skin cancers 
MT-1/2 over-expression has been found in cutaneous malignant melanomas in association 
with poor prognosis (Emri, et al., 2013; Sugita, et al., 2001; Weinlich, 2009). Over-expression 
of cancer-testis antigen 16 (CT16, PAGE5), a positive regulator of MT-2A has been 
demonstrated in melanoma metastasis (Nylund, et al., 2012). Nevertheless, MT-1E gene 
promoter methylation could be revealed in 1 of 17 (6%) of the benign naevi, in 16 of 43 
(37%) primary melanoma tumours and in 6 of 13 (46%) melanoma metastases (Faller, et al., 
2010). Higher incidence of promoter methylation of MT-1G was also demonstrated in 
melanomas compared with normal melanocytes and nevi (Koga, et al., 2009). Ectopic over-
expression of MT-1E has been demonstrated to increase the sensitivity of melanoma cells to 
cisplatin-induced apoptosis (Faller, et al., 2010). Low MT-3 protein expression has been 
demonstrated in normal skin epidermis (Pula, et al., 2015; Slusser, et al., 2015). Significantly 
higher MT-1/2 and MT-3 expression was noted in actinic keratosis and cutaneous squamous 
cell cancer, as compared with normal skin epidermis, whereas very low levels of MT-3 
expression were found in basal cell cancer (Pula, et al., 2015; Slusser, et al., 2015; Zamirska, 
Matusiak, Dziegiel, Szybejko-Machaj, & Szepietowski, 2012). Table 10 summarizes of MTs 
(sub)isoforms expression studies in other human cancer cell lines. 
 















Above chapter gives clear evidence that due to their roles and altered expressions in tumours 
MTs could be targeted to enhance the efficiency of anticancer therapy (Lai, Yip, & Bay, 
2011). Noteworthy, pretreatment with MT inducers can improve chemotherapy tolerance by 
decreasing the toxic effects of cytostatics on non-target organs (Heger, et al., 2016). On the 
other hand, this action can result in significant increase of chemoresistance of cancer cells. 
Thus, specific knowledge on particular roles of MTs has to be obtained. SiRNA silencing of 
MTs was already published in (Lai, et al., 2010; Tarapore, Shu, Guo, & Ho, 2011), where 
Tarapore et al. used phage Phi29 Motor pRNA as a vehicle to carry siRNA specifically 
targeted to MT-2A mRNA in ovarian cancers (Tarapore, et al., 2011). Lai et al. (Lai, et al., 
2010) reported that silencing of MT-2A gene by siRNA induces entosis in MCF-7 breast 
cancer cells. Targeting of a unique mRNA molecule using antisense approaches, based on 
sequence specificity of double-stranded nucleic acid interactions should, in theory, allow for 
design of drugs with high specificity for intended targets. Antisense-induced degradation or 
inhibition of translation of a target mRNA is potentially capable of inhibiting the expression 
of any target protein (Jason, Koropatnick, & Berg, 2004). Downregulation of MTs by 
antisense RNA/DNA is known to inhibit growth of various types of tumour cells. Using this 
strategy it is possible to inhibit the growth and metastases of breast cancer cells 
(AbdelMageed & Agrawal, 1997), leukemia P388 cells, Ehrlich carcinoma, sarcoma 180 
(Takeda, et al., 1997) and nasopharyngeal cancer cells (O. J. K. Tan, Bay, & Chow, 2005). 
Antisense MT mRNA may also induce sensitivity of the cancer cells to cytostatic, either 
heavy metal-based (Kennette, Collins, Zalups, & Koropatnick, 2005) or others, such as 
anthracyclines (Wulfing, et al., 2007; Yap, et al., 2009) and kinase inhibitors (X. F. Sun, et al., 
2016). 
Cisplatin resistance was inhibited in mouse melanoma cell line by RNA interference using 















MT expression by antisense MT mRNA caused increasing of tumour cells sensitivity to 
cisplatin (Kennette, et al., 2005). Use of sorafenib, a tyrosine kinase inhibitor, leads to a 
survival benefit in patients with advanced HCC, but its use is hampered by drug resistance. 
Targeting MT-1G enhances the anticancer activity of sorafenib in vivo, where suppression of 
MT-1G expression increased sorafenib sensitivity and negative regulation of ferroptosis in 
Huh7 and HepG2 cells (X. F. Sun, et al., 2016).  
Another potential role of MT in cancer therapy is its protective action during chemotherapy 
(Volm, 1998). Overall, cells with developed resistance to heavy metal-based cytostatics have 
often increased expression of MTs (Bredel, 2001; Chao, 1996; Naito, Yokomizo, & Koga, 
1999; Perez, 1998; Scanlon, Kashanisabet, Tone, & Funato, 1991). Targeting the MTs with 
antisense RNA/DNA for reversal of multidrug resistance was successfully proposed (Gosland, 
Lum, Schimmelpfennig, Baker, & Doukas, 1996), and could be considered as pivotal part of 
personalized cancer therapy. 
Although the use of these approaches demonstrates very promising results, we anticipate that 
further detailed insights into the complex kingdom of MTs may bring higher therapeutic 
efficiency. For instance, antisense-based therapy can be targeted to multiplex targets, not only 
one specific sub-isoform. This can enable for possible multiplication of therapeutic effects, 
however a lot of experiments is still required to accelerate these applications. 
 
Conclusions and future outlooks 
MTs are crucial biological molecules with a wide range of roles. Particularly, in cancer 
management, the detailed knowledge of changes in MTs expression on sub-isoforms levels 
allows for a proposal of systems for silencing or restoring their expression with the aim to 
modulate the efficiency of the treatment protocol and to enhance the patient’s outcome. It is 















of MTs could be also helpful to enhance the diagnostic possibilities and patient’s stratification 
for personalized treatment. Despite fast advances in the field of analytical chemistry, the 
proper identification of MTs on a protein level is still complicated. Anyway, we believe that 
such methods will allow for exact understanding of expression of certain subisoforms. This 
progress will accelerate the description of the biological roles of certain MTs, which are 
indisputably pivotal for a number of pathophysiological processes. 
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Captions for Figures  
Figure 1 
Knowledge of MTs different expression and regulation in tumour diseases is usable for their 
treatments.  
Figure 2  
Overview of methods for determination of MTs expression with respect to features important 
in research of tumour diseases. For more information to single methods see (Haq, Mahoney, 







































Table 1. Overview of human MT classification 
MT Isoform (Sub)isoform Gene symbol Gene name Previous Symbols Synonyms Locus 
MT 1 A MT-1A metallothionein 1A MT1, MT1S  16q13 
  B MT-1B metallothionein 1B MT1, MT1Q  16q13 
  E MT-1E metallothionein 1E MT1 MTD 16q13 
  F MT-1F metallothionein 1F MT1  16q13 
  G MT-1G metallothionein 1G MT1 MT1K 16q13 
  H MT-1H metallothionein 1H MT1  16q13 
  1HL1 MT-1HL1 metallothionein 1H like 1 MT1P2  1q43 
  M MT-1M metallothionein 1M MT1, MT1K  16q13 
  X MT-1X metallothionein 1X MT1 MT-1l 16q13 
   MT-1CP metallothionein 1C, pseudogene   16q13 
   MT-1DP metallothionein 1D, pseudogene  MTM 16q13 
   MT-1IP metallothionein 1I, pseudogene MT1, MT1I MTE 16q13 
   MT-1JP metallothionein 1J, pseudogene MT1, MT1NP, MT1J MTB 16q13 
   MT-1L metallothionein 1L, pseudogene MT1 MTF, MT1R 16q13 
   MT-1P1 metallothionein 1 pseudogene 1  bA435O5.3 9q22.32 
   MT-1P3 metallothionein 1 pseudogene 3 C20orf127, MTL4 dJ614O4.6 20q11.22 
MT 2 A MT-2A metallothionein 2A MT2  16q13 
MT 3  MT-3 metallothionein 3  GIF 16q13 















Table 2. Summary of MTs (sub)isoforms expression studies in human tumours. Up- and 
down regulation is related to surrounding non-tumour tissues, if not mentioned otherwise.   
Diagnosis Gene Tissue sample Observation Citation 
Prostate cancer MT-1F Perineural-invasive CaP downregulation (Prueitt, et al., 
2008) 
MT-1G CaP  hypermethylation (Henrique, et 
al., 2005) 
MT-1H CaP  hypermethylation (Han, et al., 
2013) 
MT-1M Perineural-invasive CaP  downregulation (Prueitt, et al., 
2008) 
MT-1X Advanced CaP  downregulation (Garrett, et al., 
2000) 
Gastric cancer MT-1A cisPt-resistant gastric cancer  expression (Suganuma, et 
al., 2003) 
MT-1B cisPt-resistant gastric cancer  expression (Suganuma, et 
al., 2003) 
MT-1E cisPt-resistant gastric cancer  expression (Suganuma, et 
al., 2003) 
MT-1F cisPt-resistant gastric cancer  expression (Suganuma, et 
al., 2003) 
MT-1G cisPt-resistant gastric cancer  upregulation (Suganuma, et 
al., 2003) 
MT-1JP Gastric cancer  downregulation (J. Yang, et al., 
2017) 
MT-1M Gastric cancer  downregulation (J. Yang, et al., 
2017) 
MT-2A Poor prognosis gastric cancer  
Docetaxel-responding gastric cancer  
downregulation 
upregulation 
(Pan, Huang, et 
al., 2013; Pan, 
Xing, et al., 
2013) 
(Pan, et al., 
2016) 
MT-3 cisPt resistant gastric cancer  





(Deng, et al., 
2003) 
MT4 cisPt resistant gastric cancer  expression (Suganuma, et 
al., 2003) 
Thyroid cancer MT-1E thyroid cancer  downregulation (Ferrario, et al., 
2008) 
MT-1G thyroid cancer   hypermethylation 
downregulation,  
modulation of  PI3K/Akt pathway  
(Huang, et al., 
2003) 
(J. Fu, et al., 
2013) 
(Ferrario, et al., 
2008) 
MT-1X thyroid cancer  downregulation (Ferrario, et al., 
2008)  
MT-2A thyroid cancer  downregulation (Ferrario, et al., 
2008) 
Sarcoma MT-1B osteosarcoma  upregulation (Endo-Munoz, 
et al., 2010) 
MT-1E osteosarcoma  upregulation (Endo-Munoz, 
et al., 2010) 
MT-1F soft tissue sarcoma  upregulation (Skubitz, et al., 
2012) 
MT-1G osteosarcoma  upregulation (Endo-Munoz, 
et al., 2010) 





















et al., 2010) 
MT-1L osteosarcoma  upregulation (Endo-Munoz, 
et al., 2010) 
MT-1X soft tissue sarcoma  upregulation (Skubitz, et al., 
2012) 




(Skubitz, et al., 
2012) 
(Endo-Munoz, 
et al., 2010) 






(Tai, et al., 
2003) 
MT-1B breast cancer  no expression (Tai, et al., 
2003) 
MT-1E breast cancer  
oestrogen negative breast cancer  
breast cancer 
downregulation in tumour area 
expression dependent on invasivity 
downregulation 
(R. X. Jin, Bay, 
Chow, Tan, et 
al., 2001) 
(R. Jin, et al., 
2000) 
(Tai, et al., 
2003) 
MT-1F breast cancer  
Different grades breast cancer tissues 
breast cancer  
downregulation in tumour area 
expression correlation with grade  
downregulation 
(R. X. Jin, Bay, 
Chow, Tan, et 
al., 2001) 
(R. X. Jin, Bay, 
Chow, & Tan, 
2001) 
(Tai, et al., 
2003) 
MT-1G breast cancer downregulation (Tai, et al., 
2003) 
MT-1H breast cancer downregulation (Tai, et al., 
2003) 
MT-1JP breast cancer  hypermethylation (Piotrowski, et 
al., 2006) 
MT-1X breast cancer  downregulation (Tai, et al., 
2003) 
MT-2A breast cancer  
breast cancer  
downregulation in tumour area 
expression 
(R. X. Jin, Bay, 
Chow, Tan, et 
al., 2001) 
(Tai, et al., 
2003) 
MT-3 breast cancer  with poor prognosis upregulation (Sens, et al., 
2001) 
Lung cancer MT-1A lung cancer  
malignant mesothelioma  
downregulation 
hypermethylation 
(Liang, et al., 
2013) 
(Tsou, et al., 
2007) 







MT-1E poor outcome NSLC  


























MT-1F bad prognosis LLC  
poor outcome NSLC  
upregulation 
upregulation 











MT-1G bad prognosis LLC  
poor outcome NSLC  













(Liang, et al., 
2013) 







MT-1M bad prognosis LLC  upregulation (da Motta, et 
al., 2015) 
MT-1X bad prognosis LLC  
poor outcome NSLC  
upregulation 
upregulation 









MT-2A lung cancer  
malignant mesothelioma  
downregulation 
hypermethylation 
(Liang, et al., 
2013) 
(Tsou, et al., 
2007) 
MT-3 lung tissue from patients exposed to 
sulfur mustard 
malignant NSLC  














Jethon, et al., 
2013) 
(Liang, et al., 
2013) 
MT4 lung cancer  downregulation (Liang, et al., 
2013) 
Ovarian cancer MT-1L low malignant potential/early cancer 
onset  
downregulated (Mougeot, et 
al., 2006) 
MT-1X low malignant potential/early cancer 
onset  
downregulation (Mougeot, et 
al., 2006) 
MT-2A low malignant potential/early cancer 
onset  



















MT-1E Melanoma  hypermethylation, cisPt sensitivity (Faller, et al., 
2010) 
MT-3 actinic keratosis  
basal cell carcinoma  
SCC 





moderate to intense expression 
low to moderate expression 
(Pula, et al., 
2015) 
(Pula, et al., 
2015) 
(Pula, et al., 
2015) 
(Slusser, et al., 
2015) 
(Slusser, et al., 
2015) 




MT-1E RCC  downregulation (M. Takahashi, 
et al., 2001) 
MT-1G RCC  downregulation (Alkamal, et 
al., 2015; 




MT-1H RCC  downregulation (Alkamal, et 
al., 2015; M. 
Takahashi, et 
al., 2001) 
MT-1L RCC  downregulation (M. Takahashi, 
et al., 2001) 






(Nguyen, et al., 
2000) 









et al., 2013) 
(H. Li, Lu, 
Chen, & Liu, 
2017) 
MT-1E ICC downregulation (Tarapore, et 
al., 2011) 






Hepatocytes from primary HCC 
downregulation 
downregulation, methylation 





(Kanda, et al., 
2009) 
(K. Y. Y. 
Chan, et al., 
2006) 
(C. L. Fu, Pan, 
Pan, & Gan, 
2017) 















(Y. L. Zheng, 
et al., 2017) 
MT-1HL1 HCC downregulation (C. L. Fu, et 
al., 2017) 






















(J. Mao, et al., 
2012) 
(C. L. Fu, et 
al., 2017) 
(Ji, et al., 
2014) 
MT-1X ICC downregulation (Tarapore, et 
al., 2011) 






MT-1E DLBCL ABC  upregulation (Poulsen, et al., 
2006) 
MT-1F DLBCL ABC  upregulation (Poulsen, et al., 
2006) 
MT-1G DLBCL ABC  upregulation (Poulsen, et al., 
2006) 
MT-1H DLBCL ABC  upregulation (Poulsen, et al., 
2006) 
MT-1L DLBCL ABC  upregulation (Poulsen, et al., 
2006) 
MT-1M DLBCL ABC  upregulation (Poulsen, et al., 
2006) 
MT-1X DLBCL ABC  upregulation (Poulsen, et al., 
2006) 
MT-2A DLBCL ABC  upregulation (Poulsen, et al., 
2006) 
MT-3 AML  hypermethylation, downregulation (Y. F. Tao, et 
al., 2014) 
Head and neck 
cancer 
MT-1A OSCC  downregulation (X. Yang, et 
al., 2014) 
MT-1E OSCC  upregulation (Brazao-Silva, 
et al., 2015) 
MT-1F OSCC  upregulation (Brazao-Silva, 
et al., 2015) 




(Kumar, et al., 
2007) 
(Brazao-Silva, 
et al., 2015) 
MT-1H OSCC  downregulation (Brazao-Silva, 
et al., 2015) 




(Oka, et al., 
2009) 
(Y. C. Lee, et 
al., 2011) 
MT-1X OSCC  downregulation (Brazao-Silva, 
et al., 2015) 
MT-2A OSCC  upregulation (Brazao-Silva, 
et al., 2015) 






(E. Smith, et 
al., 2005) 
(Brazao-Silva, 
et al., 2015) 
(D. F. Peng, et 
al., 2011) 
MT4 OSCC  downregulation (Brazao-Silva, 
et al., 2015) 
Endometrium 
cancer 
MT-1A p53 mutant UCEC  gene loss (Delaney & 
Stupack, 2016) 
MT-1E p53 mutant UCEC  gene loss (Delaney & 
Stupack, 2016) 
MT-1F p53 mutant UCEC  gene loss (Delaney & 
Stupack, 2016) 
















MT-1H p53 mutant UCEC  gene loss (Delaney & 
Stupack, 2016) 
MT-1X p53 mutant UCEC  gene loss (Delaney & 
Stupack, 2016) 




MT-1A crc  downregulation (Arriaga, et al., 
2012) 
MT-1B crc  downregulation (Jansova, et al., 
2006) 
MT-1E crc  downregulation (Arriaga, et al., 
2012; Yan, et 
al., 2012) 
MT-1F crc  




(Jansova, et al., 
2006; Yan, et 
al., 2012) 
(Szelachowska, 
et al., 2012) 
MT-1G crc  downregulation (Arriaga, et al., 
2012; Jansova, 
et al., 2006; 
Yan, et al., 
2012) 
MT-1H crc  downregulation (Arriaga, et al., 
2012; Jansova, 
et al., 2006; 
Yan, et al., 
2012) 
MT-1M crc  downregulation (Arriaga, et al., 
2012) 
MT-1X crc  
crc  
rectal adenocarcinoma after 
radiotherapy 





(Arriaga, et al., 
2012; Yan, et 
al., 2012) 
(Szelachowska, 
et al., 2012) 
MT-2A crc  




(Jansova, et al., 
2006) (Arriaga, 
et al., 2012) 
(Szelachowska, 
et al., 2012) 
CNS tumours 
 
MT-1A short survival glioblastoma multiforme  upregulation (Mehrian-Shai, 
et al., 2015) 
MT-1B bone marrow from neuroblastoma 
patients 
short survival glioblastoma multiforme  
overexpression 
upregulation 
(Scaruffi, et al., 
2012) 
(Mehrian-Shai, 
et al., 2015) 
MT-1E bone marrow from neuroblastoma 
patients 
short survival glioblastoma multiforme  
overexpression 
upregulation 
(Scaruffi, et al., 
2012) 
(Mehrian-Shai, 
et al., 2015) 
 MT-1F short survival glioblastoma multiforme  upregulation (Mehrian-Shai, 
et al., 2015) 
MT-1G bone marrow from neuroblastoma 
patients 
overexpression (Scaruffi, et al., 
2012) 
MT-1H bone marrow from neuroblastoma 
patients 
short survival glioblastoma multiforme  
overexpression 
upregulation 
(Scaruffi, et al., 
2012) 
(Mehrian-Shai, 
et al., 2015) 
MT-1HL1 bone marrow  from neuroblastoma 
patients 
overexpression (Scaruffi, et al., 
2012) 
MT-1L bone marrow from neuroblastoma 
patients 
short survival glioblastoma multiforme  
overexpression 
upregulation 

















et al., 2015) 
MT-1X bone marrow from neuroblastoma 
patients 
overexpression (Scaruffi, et al., 
2012) 
MT-2A bone marrow from neuroblastoma 
patients 
overexpression (Scaruffi, et al., 
2012) 
MT-3 short survival glioblastoma multiforme  upregulation (Mehrian-Shai, 
et al., 2015) 
Bladder cancer MT-1X bladder cancer  upregulation (Somji, et al., 
2001) 
 
Abbreviations: CaP – prostate cancer, NSLC – non-small cell lung cancer, LLC – lung large-
cell carcinoma, SCC – squamous cell carcinoma, BCC – basal cell carcinoma, RCC – renal 
cell carcinoma, APA - adrenocortical aldosterone-producing adenoma, ICC – intrahepatic 
cholangiocarcinoma, HCC – hepatocellular carcinoma, DLBCL – diffuse large B-cell 
lymphoma, ABC – activated B-cell, AML – acute myeloid leukaemia, OSCC – oral squamous 
cell carcinoma. ESCC – oesophageal squamous cell carcinoma, EAC – oesophageal 

















Table 3. Summary of MTs (sub)isoforms expression studies in human prostate cancer cell 
lines. Up- and down regulation is related to non-treated cells, if not mentioned otherwise.   






C/EBP alpha expression 



















C/EBP alpha expression 



























LNCaP C/EBP alpha expression downregulation (Yin, et al., 
2005) 
PC-3 C/EBP alpha expression downregulation (Yin, et al., 
2005) 
RWPE-1 Cu2+ upregulation (Bigagli, et 
al., 2010) 
VCAP Disulfiram downregulation (Iljin, et al., 
2009) 








Zn2+ or Cd2+ in presence of Ca2+ 
upregulation 





LTL313h (XG) Genistein upregulation (Nakamura, 
et al., 
2013) 




LNCaP C/EBP alpha expression downregulation (Yin, et al., 
2005) 
PC-3 C/EBP alpha expression downregulation (Yin, et al., 
2005) 
RWPE-1 Zn2+ and Cd2+  upregulation (Albrecht, 
et al., 
2008) 




LNCaP Zn2+ upregulation (D. J. 
Smith, et 
al., 2006) 



















VCAP Disulfiram downregulation (Iljin, et al., 
2009) 





LNCaP C/EBP alpha expression downregulation (Yin, et al., 
2005) 




(Yin, et al., 
2005) 
(Han, et al., 
2013) 
RWPE-1 Cu2+ 








LTL313h (XG) Genistein upregulation (Nakamura, 
et al., 
2013) 



















PC-3 Zn2+ upregulation (Lin, et al., 
2009) 















PC-3 Hypoxia upregulation (Yamasaki, 
et al., 
2007) 
RWPE-1 Zn2+ or Cd2+ in presence of Ca2+ Ca2+ -modified regulation (Singh, et 
al., 2008) 
VCAP Disulfiram downregulation (Iljin, et al., 
2009) 

















LNCaP C/EBP alpha expression 































PC-3 C/EBP alpha expression 













Zn2+ or Cd2+ in presence of Ca2+ 
upregulation 





VCAP Disulfiram downregulation (Iljin, et al., 
2009) 
LTL313h (XG) Genistein upregulation (Nakamura, 
et al., 
2013) 
C4-2 Zn2+ upregulation (D. J. 
Smith, et 
al., 2006) 
EPN Raloxifene upregulation (Rossi, et 
al., 2011) 













(Yin, et al., 
2005)  
(Lin, et al., 
2009) 
Abbreviations: XG – xenograft, MIC-1 – macrophage inhibitory cytokine 1, C/EBP alpha – 
















Table 4. Summary of MTs (sub)isoforms expression studies in human lung cancer cell lines. 
Up- and down regulation is related to non-treated cells, if not mentioned otherwise.   
Gene Cell line Treatment Observation Citation 
MT-1A NCI-H526 Titanocene C upregulation (Olszewski, 
et al., 
2011) 
SAE  THC upregulation (Sarafian, 
et al., 
2005) 
MT-1B NCI-H526 Titanocene C upregulation (Olszewski, 
et al., 
2011) 





no treatment upregulation (da Motta, 
et al., 
2015) 























no treatment upregulation (da Motta, 
et al., 
2015) 
























MT-1H NCI-H526 Titanocene C upregulation (Olszewski, 
et al., 
2011) 





















































MT-1HL1 A-549 MGd upregulation (Magda, et 
al., 2005) 
MT-1JP NCI-H526 Titanocene C upregulation (Olszewski, 
et al., 
2011) 
































no treatment upregulation (da Motta, 
et al., 
2015) 





no treatment upregulation (da Motta, 
et al., 
2015) 















































































cisPt resistance upregulation (Y. Y. 
Yang, et 
al., 1994) 
MT-3 A-549 Rosiglitazone 
Carboplatin 





















downregulation due to GpG 









Abbreviations: SAE – small airway epithelial cells, THC – delta-9-tetrahydrocannabinol, 
















Table 5. Summary of MTs (sub)isoforms expression studies in human breast cancer cell lines. 
Up- and down regulation is related to non-treated cells, if not mentioned otherwise.   
Gene Cell line Treatment Observation Citation 








(Calaf & Roy, 
2007) 
(Calaf & Roy, 
2007) 
(Calaf & Roy, 
2007) 


















no treatment expression (Tai, et al., 
2003) 




(Gelfand, et al., 
2017) 
(Tai, et al., 
2003) 






(Sirchia, et al., 
2008) 















































(Chuang, et al., 
2002) 
(Chuang, et al., 
2002) 
(Chuang, et al., 
2002) 
(Wierzowiecka, 

















Todd, & Sens, 
1998; Tai, et 
al., 2003) 
(Ostrakhovitch, 
et al., 2016) 








(Calaf & Roy, 
2007) 
(Calaf & Roy, 
2007) 
























et al., 2016) 
(Friedline, et 
al., 1998; Tai, 
et al., 2003)  
Hs 578T no treatment expression (Friedline, et 
al., 1998; Tai, 





no expression  
 
(Friedline, et 
al., 1998; Tai, 
et al., 2003) 
 
HB2 Cd2+ downregulation (Sirchia & 
Luparello, 
2009) 





Zn2+ upregulation (Wierzowiecka, 


























(Gelfand, et al., 
2017) 
(Scibetta, et al., 
2007) 
(Wierzowiecka, 
et al., 2016) 








































et al., 2016) 
(Tai, et al., 
2003) 












et al., 2010) 
(Worthington, 
et al., 2010) 
ME16C 
SK-BR-3 
Zn2+ upregulation (Wierzowiecka, 
et al., 2016) 












(Gelfand, et al., 
2017) 
(Chuang, et al., 
2002) 
(Chuang, et al., 
2002) 
(Chuang, et al., 
2002) 
(Wierzowiecka, 
et al., 2016) 
(Tai, et al., 
2003) 
 MCF-10F Parathion 
Estrogen 




(Calaf & Roy, 
2007) 
(Calaf & Roy, 
2007) 
(Calaf & Roy, 
2007) 









et al., 2016) 
(Sirchia, et al., 
2008) 
(Tai, et al., 
2003) 














et al., 2010) 
(Worthington, 
et al., 2010) 
ME16C Zn2+ upregulation (Wierzowiecka, 
et al., 2016) 















et al., 2016) 












(Gelfand, et al., 
2017) 
(Chuang, et al., 
2002) 
(Chuang, et al., 
2002) 
(Chuang, et al., 
2002) 
(Scibetta, et al., 
2007) 








(Calaf & Roy, 
2007) 
(Calaf & Roy, 
2007) 
(Calaf & Roy, 
2007) 
MCF-12A Ethanol upregulation (Gelfand, et al., 
2016) 




(Tai, et al., 
2003) 












et al., 2010) 
(Worthington, 
et al., 2010) 








(Gelfand, et al., 
2017) 
(Chuang, et al., 
2002) 
(Chuang, et al., 
2002) 
(Chuang, et al., 
2002) 
MCF-12A Ethanol upregulation (Gelfand, et al., 
2016) 
MDA-MB-648 compared to BT-549 downregulation in MDA (Tripathi, et al., 
2005) 
 HB2 Cd
2+ downregulation (Sirchia & 
Luparello, 
2009) 





et al., 2010) 
(Worthington, 

































(Gelfand, et al., 
2017) 
(Chuang, et al., 
2002) 
















(Chuang, et al., 
2002) 
(Scibetta, et al., 
2007) 
(Wierzowiecka, 
et al., 2016) 
(Friedline, et 
al., 1998) (Tai, 
et al., 2003) 
(Ostrakhovitch, 
et al., 2016) 








(Calaf & Roy, 
2007) 
(Calaf & Roy, 
2007) 
(Calaf & Roy, 
2007) 






















al., 1998) (Tai, 
et al., 2003) 
(Wierzowiecka, 




no treatment expression (Tai, et al., 
2003) 
(Friedline, et 
al., 1998)  




Zn2+ upregulation (Wierzowiecka, 






et al., 2010) 
(Worthington, 
et al., 2010) 
MT-2A MCF-7 HIPK2 depletion 
Cd2+ 
























loss of expression sensitivity 
proliferation and cell cycle arrest 











(Gelfand, et al., 
2017) 
(Chuang, et al., 
2002) 
(Chuang, et al., 
2002) 

















et al., 2016) 
(Wierzowiecka, 
et al., 2016) 
(Tai, et al., 
2003) 
(Ostrakhovitch, 
et al., 2016) 
(Ostrakhovitch, 
et al., 2016) 
 
(Lim, Jocelyn, 
Yip, & Bay, 
2009) 








(Calaf & Roy, 
2007) 
(Calaf & Roy, 
2007) 
(Calaf & Roy, 
2007) 

























(H. G. Kim, et 
al., 2011) 
(Wierzowiecka, 
et al., 2016) 
(Friedline, et 
al., 1998) (Tai, 
et al., 2003) 







expression (Friedline, et 
al., 1998; Tai, 
et al., 2003) 




Zn2+ upregulation (Wierzowiecka, 
et al., 2016)  
HB2 Cd2+ downregulation (Sirchia & 
Luparello, 
2009) 
MT-3 MCF-7 Ethanol upregulation (Gelfand, et al., 
2017) 







et al., 2010)  
(Worthington, 
et al., 2010) 
HME PEITC upregulation (Telang, 
Braeau, & 
Morris, 2009) 
MT4 MCF-7 Ethanol upregulation (Gelfand, et al., 
2017) 
















MDA-MB-231 Cd2+ no expression (Sirchia, et al., 
2008) 
Abbreviations: EGF – epithelial growth factor, HRG – heregulin, TBH - t-butyl 
hydroperoxide, PLU/JARID18 – transcriptional repressor, member of ARID DNA binding 
proteins, PEITC -  Phenethyl isothiocyanate, HIPK2 - Homeodomain-interacting protein 
















Table 6. Summary of MTs (sub)isoforms expression studies in human colorectal cancer cell 
lines. Up- and down regulation is related to non-treated cells, if not mentioned otherwise.   
Gene Cell line Treatment Observation Citation 
MT-1A CaCo-2 Arsenic species upregulation (Calatayud, 
Devesa, & 
Velez, 2013) 








WiDr SPINK1 knock-down upregulation (Tiwari, et al., 
2015) 






(Bajak, et al., 
2015) 
WiDr SPINK1 knock-down upregulation (Tiwari, et al., 
2015) 





no treatment  
inhibition of tumorigenicity 
hypermethylation 
(Yan, et al., 
2012) 
LoVo no treatment hypermethylation (Yan, et al., 
2012) 
MT-1G CaCo-2 Rosiglitazone and/or AS601245 upregulation (Cerbone, et 
al., 2012) 




Tumour tissue DNA 





differential genes regulation 












HCT-116 MT-1G transfection and Zn2+ chemotherapy sensitization (Arriaga, et 
al., 2014) 
MT-1H CaCo-2 15-lipoxygenase-1 expresion 























(Tiwari, et al., 
2015) 
(Prasmickaite, 
et al., 2006) 
HT-29 Tumour tissue DNA  upregulation (Furi, et al., 
2015) 
MSI crc no treatment upregulation (Giacomini, 

















CaCo-2 Rosiglitazone and/or AS601245 upregulation  (Cerbone, et 
al., 2012) 
HT-29 Tumour tissue DNA downregulation (Furi, et al., 
2015) 
MT-1L CaCo-2 15-lipoxygenase-1 expresion upregulation (Nixon, et al., 
2004) 
WiDr SPINK1 knock-down  upregulation (Tiwari, et al., 
2015) 
MT-1M CaCo-2 Rosiglitazone and/or AS601245 upregulation (Cerbone, et 
al., 2012) 
WiDr SPINK1 knock-down upregulation (Tiwari, et al., 
2015) 













et al., 2006)  
(Tiwari, et al., 
2015) 
HT-29 Tumour tissue DNA upregulation (Furi, et al., 
2015) 
HCT-116 Butyrate upregulation (H. T. Tan, et 
al., 2008) 
MSI crc no treatment upregulation (Giacomini, 
et al., 2005) 














(Nixon, et al., 
2004) 
WiDr SPINK1 knock-down in WiDr cell line upregulation (Tiwari, et al., 
2015) 




(Furi, et al., 
2015) 
(H. Y. Jin, 
Tan, Liu, & 
Ding, 2010) 








(H. Y. Jin, et 
al., 2010) 
 
MSI crc no treatment upregulation (Giacomini, 
et al., 2005) 
Abbreviations: SPINK1 - Serine Protease Inhibitor Kazal-Type 1, AS601245 – JNK inhibitor 















Table 7. Summary of MTs (sub)isoforms expression studies in human hepatic cancer cell 
lines. Up- and down regulation is related to non-treated cells, if not mentioned otherwise.   
Gene Cell line Treatment Observation Citation 
MT-1A Hep G2 Mutant thyroid hormone receptor 
Cd2+ 













(Chung, et al., 
2006) 
(He, et al., 
2016) 
Huh-7 HCV core proteins expression upregulation (K. Li, Prow, 
Lemon, & 
Beard, 2002) 
Bel-7402 Tanshinone IIA upregulation (Dai, et al., 
2012) 







Fabbri, et al., 
2012) 
(He, et al., 
2016) 




(K. Li, et al., 
2002) 
(Houessinon, 
et al., 2016) 















(Yu, et al., 
2014)  






(Yu, et al., 
2014)  
 




(Yu, et al., 
2014)  
MT-1E Hep G2 Mutant thyroid hormone receptor 
Cd2+  




(Rosen, et al., 
2011) 
(Fabbri, et al., 
2012) 
(Chung, et al., 
2006) 




(K. Li, et al., 
2002) 
(Houessinon, 
et al., 2016) 







Fabbri, et al., 
2012) 
(He, et al., 
2016) 
























(Rosen, et al., 
2011) 




Fabbri, et al., 
2012) 
(X. F. Sun, et 
al., 2016) 




(K. Li, et al., 
2002) 
(Houessinon, 
et al., 2016; 
X. F. Sun, et 
al., 2016) 
Hep 3B Sorafenib  
no treatment 
upregulation 
downregulation, allelic lost 
(X. F. Sun, et 
al., 2016) 
(K. Y. Y. 





no treatment  downregulation, 
methylation 








no treatment downregulation, allelic lost (K. Y. Y. 
Chan, et al., 
2006) 




decrease of viability and 




Fabbri, et al., 
2012) 
(Y. L. Zheng, 









decrease of viability and 
invasivity via regulating 
Wnt pathway 
(K. Li, et al., 
2002) 
(Houessinon, 
et al., 2016) 
(Y. L. Zheng, 
et al., 2017) 







(He, et al., 
2016) 
MT-1JP Hep G2 Cd
2+ upregulation (Fabbri, et al., 
2012) 




(Rosen, et al., 
2011) 
(Fabbri, et al., 
2012) 
Huh-7 Sorafenib upregulation (Houessinon, 
et al., 2016) 
MT-1M Hep G2 no treatment 
Cd2+ 
SPIONs 





tumour growth inhibition 
stimulation of tumour 
growth 




Fabbri, et al., 
2012) 
(He, et al., 
2016) 
(C. L. Fu, et 
al., 2017) 
Huh-7 Sorafenib 
MT-1M overexpression  
hypermethylation 
tumour growth inhibition 
(Houessinon, 















MT-1M knock-down stimulation of tumour 
growth 
























MT-1P3 Hep G2 Cd
2+ upregulation (Cartularo, et 
al., 2015) 
MT-1X Hep G2 Cd
2+ 
MT-1X knock-out  









Fabbri, et al., 
2012) 
(Cai, et al., 
2014) 
(Chung, et al., 
2006) 
(He, et al., 
2016) 
MT-2A Hep G2 Pb
2+ 
Cd2+ 










(Fabbri, et al., 
2012) 
(Chung, et al., 
2006) 
(He, et al., 
2016) 
VL17A Ethanol and/or Zn2+ upregulation (Liuzzi & 
Yoo, 2013) 
MT-3 Huh-7 HCV core proteins expression upregulation (K. Li, et al., 
2002) 
Abbreviations: SPIONs – superparamagnetic iron oxide nanoparticles, HCV – hepatitis C 
virus, SMM22 alpha - Smooth muscle protein 22-alpha, Yap - Yes associated protein, RunX2 
















Table 8. Summary of MTs (sub)isoforms expression studies in human head and neck cancer 
cell lines. Up- and down regulation is related to non-treated cells, if not mentioned otherwise.   

































































































HepG2 Mutant thyroid receptor downregulated (Rosen, 
et al., 
2011) 












































































no treatment expression 
 













HK1 NPC Hypericin upregulation (Du, et 
al., 
2006) 














































































Abbreviations: HNF1A-AS1 - HNF1A antisense RNA 1, TCRP-1 - tongue cancer resistance-

















Table 9. Summary of MTs (sub)isoforms expression studies in human haematological cancer 
cell lines. Up- and down regulation is related to non-treated cells, if not mentioned otherwise.   





















K-562 PMA downregulation (Bagheri, et 
al., 2009) 
NB4 Nucleostemin knock-out downregulation (Sun, Jia, 























K-562 PMA downregulation (Bagheri, et 
al., 2009) 
NB4 Nucleostemin knock-out downregulation (X. L. Sun, 














K-562 PMA upregulation (Bagheri, et 
al., 2009) 
NB4 Nucleostemin knock-out downregulation (X. L. Sun, 
















upregulation (Bagheri, et 
al., 2009) 
K-562 PMA downregulation (Bagheri, et 
al., 2009) 
NB4 Nucleostemin knock-out downregulation (X. L. Sun, 
















upregulation (Bagheri, et 
al., 2009) 








































NB4 Nucleostemin knock-out downregulation (X. L. Sun, 





upregulation (Mensah, et 
al., 2015) 
MT-1L NB4 Nucleostemin knock-out downregulation (X. L. Sun, 







upregulation (Bagheri, et 
al., 2009) 
K-562 PMA upregulation (Bagheri, et 
al., 2009) 
NB4 Nucleostemin knock-out downregulation (X. L. Sun, 
et al., 2016) 
DoHH-2 
TMD8 








upregulation (Bagheri, et 
al., 2009) 
K-562 PMA upregulation (Bagheri, et 
al., 2009) 
NB4 Nucleostemin knock-out downregulation (X. L. Sun, 





















no treatment methylation, 
downregulation 
(Y. F. Tao, 
et al., 2014) 















Table 10. Summary of MTs (sub)isoforms expression studies in other human cancer cell 
lines. Up- and down regulation is related to non-treated cells, if not mentioned otherwise. 
Diagnosis Gene Cell line Treatment Observation Citation 
CNS 
cancer 
MT-1A U-87 As2O3 for 48 h 




a, et al., 
2012)  







 D-341 BCNU-resistance upregulation (Bacolo
d, et al., 
2002) 
MT-1E U-87 As2O3 for 48 h 




decreased motility and invasivity 
(Falnog
a, et al., 
2012) 
(Falnog












 D-341 BCNU-resistance upregulation  (Bacolo
d, et al., 
2002) 
 U-343 MT-1E knock-in increased motility and invasivity (Ryu, et 
al., 
2012) 
MT-1F U-87 As2O3 for 48 h 




a, et al., 
2012)  
 U-251 miR340-transfection upregulation (Cosset, 
et al., 
2016) 
 D-341 BCNU-resistance upregulation (Bacolo
d, et al., 
2002) 
MT-1H U-251 miR340-transfection upregulation (Cosset, 
et al., 
2016) 
 SKNBE(2) Hypoxia upregulation (Jogi, et 
al., 
2004) 
MT-1L D-341 BCNU-resistance upregulation (Bacolo
d, et al., 
2002) 
MT-1X U-87 As2O3 for 48 h 




a, et al., 
2012)  







MT-2A U-87 As2O3 for 48 h 




a, et al., 
2012)  







 D-341 BCNU-resistance upregulation (Bacolo






















As2O3 for 48 h 
As2O3 for 48 h after 48 h recovery 













MT-1A KAT-5 Cd2+ 







MT-1B KAT-5 Cd2+ 







MT-1E KAT-5 Cd2+ 







MT-1F KAT-5 Cd2+ 







MT-1G KAT-5 Cd2+ 






























tumour suppression via 
downregulation 
 
(J. Fu, et 
al., 
2013) 
 K1 MT-1G transfection increased growth and 
tumorigenicity 
(Ferrari
o, et al., 
2008) 
MT-1H KAT-5 Cd2+ 







MT-1X KAT-5 Cd2+ 












MT-2A KAT-5 Cd2+ 






























 A-498 DNA methylation inhibitor upregulation (Alkama
l, et al., 
2015) 




 A-498 DNA methylation inhibitor upregulation (Alkama
l, et al., 
2015) 




 A-498 DNA methylation inhibitor upregulation (Alkama
l, et al., 
2015) 




MT-1M A-498 DNA methylation inhibitor upregulation (Alkama
l, et al., 
2015) 
MT-1X A-498 DNA methylation inhibitor upregulation (Alkama
l, et al., 
2015) 




 A-498 DNA methylation inhibitor upregulation (Alkama
l, et al., 
2015) 
MT-3 H295R angiotensin II and forskolin upregulation (Felizol




MT-1F MKN-28 no treatment expression (Soo, et 
al., 
2011) 
MT-1X MKN-28 no treatment expression (Soo, et 
al., 
2011) 

























 SNU-1, -16, -
216,-484, -
601, -638, -
668, -719  
















































MT-1E SLT4 MT-1E overexpression  increased migration (Wu, et 
al., 
2008) 










 DBC1 expression 
 DBC1 expression 







































 MT-1B HeLa Zn




 MT-1E HeLa Cd
2+ 
Melatonin 
Cd2+ and melatonin 






























 MT-1F HeLa Cd
2+ 
Melatonin 
Cd2+ and melatonin 
























 MT-1G HeLa Zn




 MT-1H HeLa Zn




 MT-1X HeLa Cd
2+ 
Melatonin 
Cd2+ and melatonin 
















 MT-2A HeLa Cd
2+ 
Melatonin 
Cd2+ and melatonin 
zinc-pyrithione 

























 MT-3 HeLa Zn




 MT4 HeLa Zn























 MT-1M NT2/D1 STK17A knock-down upregulation (P. Mao, 
et al., 
2011) 

























MT-1E Ishikawa RU486 upregulation (Orbo, 
et al., 
2009) 
 Non-specified no treatment 
5-azacytidine 
downregulation 

















n, et al., 
2008)  
 
MT-1L Ishikawa Progesterone 








n, et al., 
2005) 
MT-2A Ishikawa Progesterone upregulation (Paulsse

























MT-2A knock-down  proliferation inhibition (Tarapor
e, et al., 
2011) 







decreased viability  (Zn chelation) 















MT-1E WM-793 No treatment gene methylation (Faller, 
et al., 
2010) 




















Abbreviations: BCNU - 1,3-bis(2-chloroethyl)-1-nitrosourea, ERK1/2 - extracellular signal-
regulated kinase 1, TSHR - thyroid stimulating hormone receptor, TSH - thyroid stimulating 
hormone, DATS – diallyl trisulphide, DOC – docetaxel, DBC1 - deleted in bladder cancer 
protein 1, NKK - 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, tobacco carcinogen, 
STK17A - Serine/Threonine Kinase 17a, RU486 – mifepristone, PRA/B – Progesterone 





MT-1H hESCs H9 irradiation upregulation (Sokolo




    
MT-2A A2058 CT16 knock-down  upregulation (Nylund
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